Subscribe to Life Science Success for cutting-edge insights, expert interviews, and a vibrant community. Your subscription fuels our mission and keeps you at the forefront of life sciences.
Chairman, CEO
Recognized leader with highly successful experience and expertise in transforming and restructuring public and private companies, establishing strong governance processes and operational discipline, resulting in operational improvements, significant revenue and enterprise value growth. During his career, he has overseen the approval of over 10 NDAs, over 15 acquisitions/divestitures, in excess of $2.5 billion in financial transactions and, led over $5 billion in incremental enterprise growth.
Key highlights of Mr. Dodd’s career include:
• Mr. Dodd joined the GeoVax Board of Directors in March 2010 and was elected Chairman in January 2011. Effective September 2018, he began serving also as the President, CEO. At the 2018 World Vaccine Congress, GeoVax received the “Best Biotech” recognition award, a reflection of the opinions of the vaccine industry public and private members. Mr. Dodd has led GeoVax through a significant transformation including a corporate recapitalization and uplisting to Nasdaq (September 2020). More recently, during 2021, GeoVax successfully executed strategic transactions resulting in the Company acquiring the exclusive worldwide rights to two Phase 2-status products. This included the most advanced multi-antigen vaccine for Covid-19 (currently in two Phase 2 trials) and Gedeptin®, a cancer immunotherapy in a multi-site Phase 2 trial, having received Orphan Drug designation from the FDA.
• During Mr. Dodd's six-year tenure as President, CEO and Director of Serologicals Corporation, he led a transformation of that Company during which the enterprise value increased over $1 billion…from $85 million to an all-cash sale to Millipore Corporation of $1.5 billion;
• Mr. Dodd served as President, CEO & Director of Solvay Pharmaceuticals, Inc., during which the enterprise value increased over $2 billion – from $100 million to $2.5 billion over a five-year period;
• As President, CEO & Director of Aeterna Zentaris, Mr. Dodd led the development of and FDA approval of Macrilen™, the first and only product successfully developed and receiving regulatory approval in the 30+history of that company;
• Mr. Dodd also served in executive roles with Wyeth-Ayerst Laboratories (now part of Pfizer), Bristol-Myers Squibb and Abbott Laboratories;
He is a frequent invited speaker and panelist at business and economic development conferences, as well as various conferences focused on the life sciences and pharmaceutical industry. Mr. Dodd is a recipient of the Oglethorpe Award for UK-US Business Relationships recognized by the British American Business Council, the Georgia BIO Industry Growth Award, and a multi-year recipient of the FastTech 50 Growth Company Award (2000-2006) while leading Serologicals Corporation and, in 2022, being selected as a recipient of the Georgia Titan 100 award.
In addition, he has served on a development committee of the MacArthur Foundation, as an advisor to the First Minister of Scotland, as the Chair of the American Foundation for Suicide Prevention, as a member of the External Advisory Board of the Petit Institute for Bioengineering & Biosciences (GaTech), as the Chair of GaBio, as a board member on the Harvard Business School Healthcare Alumni Association and, in leadership roles with numerous additional organizations. Earlier in his career (1988), Mr. Dodd was recognized by the Los Angeles City Council for his leadership in establishing a developmental childcare facility in conjunction with Womens’ Hospital in the East L.A. area.
Mr. Dodd holds Bachelor of Science and Master of Science degrees from Georgia State University and completed the Harvard Business School of Advanced Management Program.